New vaccine, extra circumstances in US, Europe: Coronavirus reside information | US & Canada

U.S. company Moderna says its vaccine is 94.5 percent effective, making it the second promising announcement in the fight against COVID-19.

  • More than 54 million people worldwide have contracted COVID-19 and 1,319,267 have died, according to Johns Hopkins University.
  • Infections, hospitalizations, and deaths continue to rise in much of the United States, and states have put new restrictions in place.
  • Governments in Europe are experiencing an alarming rise in the number of cases.

Hello and welcome to Al Jazeera’s ongoing coverage of the coronavirus pandemic. This is Jihan Abdalla.

65 virus cases with 1 cluster among WHO staff in Geneva

The World Health Organization has recorded 65 cases of coronavirus among employees at its headquarters, including at least one group of infections, an internal email from The Associated Press revealed.

The reveal came amid a spate of cases in Europe, host country Switzerland, and specifically the city of Geneva, and the email said around half of the infections occurred in people who had worked from home. But 32 were employees who had worked on the grounds of the main building.

Dow jumps 360 points on Moderna COVID-19 vaccines on the news

The Dow and S&P 500 indices rebounded Monday after Moderna said preliminary trial data showed the COVID-19 vaccine is 94.5 percent effective – the second promising announcement from the vaccine front in as many weeks .

The Dow Jones Industrial Average rose more than 364 points, or 1.23 percent, when Wall Street opened, bringing the 30-share index within striking distance of the 30,000 mark.

Read more here.

According to Moderna, preliminary data from an ongoing Phase 3 study of its experimental COVID-19 vaccine showed it was 94.5 percent effective [Hans Pennink/AP Photo]

According to Moderna, the COVID-19 vaccine is 94.5 percent effective

American biotech company Moderna Inc announced on Monday that preliminary data from an ongoing Phase 3 study of its experimental COVID-19 vaccine showed 94.5 percent effectiveness.

“This is a pivotal moment in the development of our COVID-19 vaccine candidate,” said Stephane Bancel, CEO of Moderna, in a statement. “This positive interim analysis from our Phase 3 trial has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including serious diseases.”

Read more here.

Comments are closed.